Reminder: Do not include any PHI or PII in Confluence. If you require 508 accessibility assistance or any other support for this system, then please send an email to onc-jira-questions@healthit.gov
Please provide any feedback regarding this scenario in the comment form below or by clicking here. |
---|
Max Researcher has planned an NIH-funded double-blind randomized placebo-controlled trial of a pharmaco-therapeutic agent, studying its impact on reducing high rates of relapse to opioid use upon release from incarceration and its association with poor HIV treatment outcomes. Persons with opioid use disorders with or at risk for HIV infection are concentrated within the criminal justice system.
...